Takeda/BioNumerik’s Tavocept Phase III Data Did Not Meet Primary Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda will consider terminating its licensing and development agreement for the investigational drug.
You may also be interested in...
BioNumerik’s Tavocept Fails In Neuropathy, Adds To Survival Time
Firm is looking for commercialization partner for cancer candidates, CEO tells “The Pink Sheet” DAILY.
BioNumerik’s Tavocept Fails In Neuropathy, Adds To Survival Time
Firm is looking for commercialization partner for cancer candidates, CEO tells “The Pink Sheet” DAILY.
Actos Patent Expiry Fuels Takeda’s Drive For Deals – Licensing Exec
During BIO-Asia 2007 in Tokyo, Takeda’s head of licensing outlines the strategy behind the company’s deal with Affymax.